We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat... Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke. Show more
REGULATED INFORMATIONMay 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to...
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer Mont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or...
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), March 29, 2024, 9:30 pm CET / 4:30 pm ET – In accordance with article 15 of the...
Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery FoundationFirst medical device company to become a corporate...
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints Reports an Apnea-Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis (p=0.002)Reports an Oxygen...
Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating ResultsExpect to report DREAM U.S. pivotal study efficacy and safety data by early AprilAchieved record quarterly...
Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgium – February 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext...
Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024 Mont-Saint-Guibert, Belgium – February 15, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.92 | -18.9162561576 | 10.15 | 10.5 | 8.18 | 33039 | 9.12878721 | CS |
| 4 | -1.83 | -18.1908548708 | 10.06 | 11.53 | 8.18 | 28934 | 9.64414586 | CS |
| 12 | -4.17 | -33.6290322581 | 12.4 | 20 | 8.18 | 45417 | 13.84702709 | CS |
| 26 | 2.99 | 57.0610687023 | 5.24 | 20 | 4 | 42736 | 10.63344646 | CS |
| 52 | 0.16 | 1.98265179678 | 8.07 | 20 | 4 | 23980 | 10.25038659 | CS |
| 156 | -21.79 | -72.5849433711 | 30.02 | 37 | 4 | 16907 | 11.99739254 | CS |
| 260 | -21.79 | -72.5849433711 | 30.02 | 37 | 4 | 16907 | 11.99739254 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
